Fabrication and Characterization of Taurine Functionalized Graphene Oxide with 5-Fluorouracil as Anticancer Drug Delivery Systems

Table 1 The basic pharmacokinetic parameters of 5-FU and 5-FU-Tau-GO through oral administration and intravenous injection

Parameter	Unit	Oral administration (5-FU)	Oral administration (5-FU-Tau-GO)	Intravenous injection (5-FU)	Intravenous injection (5-FU-Tau-GO)
T_1/2α	h	0.31 ± 0.5	0.41 ± 0.22	0.22 ± 0.12	0.75 ± 0.42
T_1/2β	h	0.73 ± 0.46	1.67 ± 1.15	0.44 ± 0.04	1.33 ± 0.64
V_1/F	L/kg	1.05 ± 0.04	0.62 ± 0.19	0.38 ± 0.06	0.38 ± 0.01
CL/F	L/h/kg	1.45 ± 0.09	0.69 ± 0.04	0.62 ± 0.02	0.25 ± 0.02
AUC_(0−t)	mg/L*h	17.12 ± 1.11	36.02 ± 1.83	34.62 ± 1.00	96.50 ± 8.70
AUC_(0−∞)	mg/L*h	17.33 ± 1.17	36.30 ± 1.94	40.30 ± 1.04	102.34 ± 8.71
K₁₀	1/h	1.38 ± 0.11	1.20 ± 0.36	1.66 ± 0.34	0.66 ± 0.07
K₁₂	1/h	1.68 ± 1.11	0.25 ± 0.12	1.50 ± 1.92	0.23 ± 0.26
K₂₁	1/h	1.88 ± 0.09	1.23 ± 0.80	3.25 ± 1.79	1.38 ± 1.64